Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.32 and traded as low as $2.23. Oramed Pharmaceuticals shares last traded at $2.29, with a volume of 63,993 shares trading hands.
Analyst Ratings Changes
Separately, StockNews.com downgraded Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, February 19th.
Read Our Latest Research Report on ORMP
Oramed Pharmaceuticals Price Performance
The stock has a 50-day moving average price of $2.24 and a 200-day moving average price of $2.32. The firm has a market capitalization of $91.50 million, a PE ratio of 20.36 and a beta of 1.50.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.04. As a group, equities research analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of ORMP. Boothbay Fund Management LLC grew its position in Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock worth $2,045,000 after purchasing an additional 16,857 shares during the last quarter. World Equity Group Inc. bought a new position in Oramed Pharmaceuticals during the 4th quarter valued at about $48,000. Marquette Asset Management LLC bought a new position in Oramed Pharmaceuticals during the 4th quarter valued at about $81,000. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 70,190 shares during the last quarter. Finally, Peapod Lane Capital LLC bought a new position in Oramed Pharmaceuticals during the 4th quarter valued at about $550,000. 12.73% of the stock is currently owned by institutional investors and hedge funds.
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Featured Stories
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
